Lördag 26 April | 17:58:37 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-01-30 08:00 Bokslutskommuniké 2025
2025-10-31 08:00 Kvartalsrapport 2025-Q3
2025-07-31 08:00 Kvartalsrapport 2025-Q2
2025-05-21 N/A Årsstämma
2025-05-21 08:00 Kvartalsrapport 2025-Q1
2025-05-09 N/A X-dag ordinarie utdelning MPOS 0.00 SEK
2025-01-30 - Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-07-31 - Kvartalsrapport 2024-Q2
2024-05-30 - X-dag ordinarie utdelning MPOS 0.00 SEK
2024-05-29 - Årsstämma
2024-04-30 - Kvartalsrapport 2024-Q1
2024-01-31 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-27 - Kvartalsrapport 2023-Q2
2023-05-25 - Årsstämma
2023-05-05 - X-dag ordinarie utdelning MPOS 0.00 SEK
2023-04-27 - Kvartalsrapport 2023-Q1
2023-01-30 - Bokslutskommuniké 2022
2022-11-14 - Extra Bolagsstämma 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-07-28 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning MPOS 0.00 SEK
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-28 - Bokslutskommuniké 2021
2021-08-31 - Kvartalsrapport 2021-Q2
2021-05-03 - X-dag ordinarie utdelning MPOS 0.00 SEK
2021-02-18 - Bokslutskommuniké 2020
2020-08-31 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning MPOS 0.00 SEK
2020-05-27 - Årsstämma
2020-02-28 - Bokslutskommuniké 2019
2019-11-04 - Extra Bolagsstämma 2019
2019-08-30 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning MPOS 0.00 SEK
2019-05-22 - Årsstämma
2019-02-28 - Bokslutskommuniké 2018
2018-08-30 - Kvartalsrapport 2018-Q2
2018-06-01 - X-dag ordinarie utdelning MPOS 0.00 SEK
2018-05-31 - Årsstämma
2018-02-28 - Bokslutskommuniké 2017
2017-08-30 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning MPOS 0.00 SEK
2017-05-24 - Årsstämma
2017-02-28 - Bokslutskommuniké 2016
2016-09-15 - Extra Bolagsstämma 2016
2016-08-30 - Kvartalsrapport 2016-Q2
2016-05-31 - Årsstämma
2016-05-12 - X-dag ordinarie utdelning MPOS 0.00 SEK
2016-02-29 - Bokslutskommuniké 2015
2015-08-27 - Kvartalsrapport 2015-Q2
2015-05-12 - X-dag ordinarie utdelning MPOS 0.00 SEK
2015-05-11 - Årsstämma
2015-03-10 - Extra Bolagsstämma 2015
2015-02-27 - Bokslutskommuniké 2014
2014-08-29 - Kvartalsrapport 2014-Q2
2014-05-19 - X-dag ordinarie utdelning MPOS 0.00 SEK
2014-05-16 - Årsstämma
2014-02-28 - Bokslutskommuniké 2013
2013-10-25 - Extra Bolagsstämma 2013
2013-08-29 - Kvartalsrapport 2013-Q2
2013-05-24 - X-dag ordinarie utdelning MPOS 0.00 SEK
2013-05-23 - Årsstämma
2012-12-20 - Extra Bolagsstämma 2012
2012-08-29 - Kvartalsrapport 2012-Q2
2012-05-24 - X-dag ordinarie utdelning MPOS 0.00 SEK
2012-05-23 - Årsstämma
2012-02-29 - Bokslutskommuniké 2011
2012-02-28 - Bokslutskommuniké 2012
2011-08-25 - Kvartalsrapport 2011-Q2
2011-05-20 - X-dag ordinarie utdelning MPOS 0.00 SEK
2011-05-19 - Årsstämma
2011-02-24 - Bokslutskommuniké 2010
2010-05-21 - X-dag ordinarie utdelning MPOS 0.00 SEK

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Micropos Medical är verksamt inom medicinteknik. Bolagets produkter används inom strålbehandling. Visionen är att utveckla en teknik som skall precisera sjukdomar vid nämnd behandling, där produktutvecklingen baseras på elektromagnetiskt positionssystem. Produkten skapar realtidsinformation och används främst för behandling av prostatacancer, men även vid andra tumörbehandlingar. Bolaget etablerades under 2003 och har sitt huvudkontor i Göteborg.
2025-03-27 10:00:00

Last week the Edinburgh Cancer Centre begun treating prostate cancer patients within the framework of the so-called Precision Study. Patients receive only three radiation doses, with the Raypilot System used as a complement to ensure accurate motion control during treatment, thereby minimising potential side effects. The aim is to demonstrate that three sessions work as well as five in terms of both cancer eradication and the degree of side effects.

The Pace-B study*, published in 2024, showed that SBRT** with five radiation sessions is just as effective in curing cancer as traditional treatment involving 20-40 sessions. The Precision Study aims to further streamline treatment while reducing side effects and improving patient convenience. The treatments in the study are carried out using the Raypilot System, which enables real-time monitoring of organ movement. This system allows for urethra-sparing techniques and tighter radiation margins-factors that both improve targeting accuracy and reduce the risk of side effects.

Aiming for Improved Quality of Life
The study includes 100 patients across multiple clinics in Europe and the US and is led by Professor Duncan McLaren at the Edinburgh Cancer Centre in Scotland. His aim is to make prostate cancer treatment more comfortable for patients and improving their quality of life post-treatment.

"The goal of the Precision Study is to ensure that treatment with three radiation doses does not lead to greater side effects than those observed in the Pace-B study. I am confident that we can demonstrate effective cancer treatment with less side effects," says Professor McLaren.

A Collaborative Effort for Improved Healthcare
The study was initiated by researchers at various clinics using the Raypilot System.

"Our customers are interested in developing and improving healthcare, always with patient quality of life in focus. At the same time, healthcare providers across the Western world are striving to reduce treatment times and enhance both quality and efficiency. This study could contribute to such progress, benefiting all stakeholders-healthcare providers reduce costs while improving care, and patients gain a better quality of life," says Thomas Lindström, MD at Micropos Medical AB, the company behind the Raypilot System.

The first conclusions from the Precision Study are expected within one to two years, followed by a further five years of patient follow-up before final results can be presented.

* Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer, van As et al, N Engl J Med 2024;391:1413-1425

** SBRT (Stereotactic Body Radiation Therapy) involves treatment in five or fewer sessions, over five or fewer consecutive days, with a significantly higher radiation dose per session compared to traditional treatment.

For further information, contact: 

Thomas Lindström

+46 (0)31-760 80 05
thomas.lindstrom@micropos.se